<DOC>
	<DOC>NCT00117104</DOC>
	<brief_summary>The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or subjects converted from rHuEPO therapy administered IV thrice weekly (TIW).</brief_summary>
	<brief_title>Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with end stage renal disease (ESRD) on hemodialysis Known hypersensitivity to Aranesp® (darbepoetin alfa) or any of its excipients Participating in an investigational drug or device trial Patient will not be available for followup assessment Patient has any disorder that compromises the ability of the patient to give written informed consent and/or to comply with study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>End Stage Renal Disease (ESRD)</keyword>
	<keyword>Kidney Disease, Dialysis</keyword>
	<keyword>Aranesp®, rHuEPO</keyword>
	<keyword>Anemia, Hemoglobin</keyword>
	<keyword>Dosing, Amgen</keyword>
</DOC>